.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DI54_CeftolozaneAndTazobactam.CeftolozaneAndTazobactam

Information

Ceftolozane and tazobactam is a combination of a cephalosporin antibiotic (ceftolozane) and a β-lactamase inhibitor (tazobactam). It is used for the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis. The combination is approved for clinical use and has activity against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa.

Pharmacokinetics

Pharmacokinetic parameters obtained in healthy adult subjects, both male and female, age range approximately 18–50 years, following intravenous infusion.

References

1. Larson, KB, et al., & Rizk, ML (2019). Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections. Antimicrobial agents and chemotherapy 63(6) –. DOI:10.1128/AAC.02578-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30962340

2. Monogue, ML, et al., & Kuti, JL (2016). Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. Antimicrobial agents and chemotherapy 60(11) 6578–6584. DOI:10.1128/AAC.01566-16 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27550351

3. Al Jalali, V, et al., & Zeitlinger, M (2021). Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study. The Journal of antimicrobial chemotherapy 76(9) 2342–2351. DOI:10.1093/jac/dkab166 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34050650

Revisions

• 06/2025 initial generated model